AC Immune SA (ACIU) News
Follow AC Immune SA (ACIU) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
AC Immune Price Target Maintained With a $8.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 09:31 AM UTC
L
AC Immune SA (ACIU) Hits Safety, Immunogenicity Goals in Phase 2 Part 1
AC Immune said Part 1 of its Phase 2 VacSYn trial in early Parkinson’s met safety, tolerability and immunogenicity endpoints, with 100% of treated patients generating antibodies and CSF penetration observed. Part 2 desig
REGULATION | Sep 23, 2026, 11:03 AM UTC
L
ACIU - AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
ACIU - AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
NEWS | Sep 23, 2026, 11:01 AM UTC
M
AC Immune reports favorable Phase 1 data for ACI-19764
AC Immune SA said early Phase 1 results for ACI-19764 showed the orally administered NLRP3 inflammasome drug was safe and well tolerated, with brain penetration and dose-dependent IL-1beta inhibition.
EQUITY | Aug 20, 2026, 04:32 PM UTC
H
ACIU reports positive preliminary Phase 1 data for Aci-19764
ACIU Ac immune says its NLRP3 inhibitor Aci-19764 shows positive preliminary Phase 1 findings, including reported safety/tolerability and confirmed CSF penetration, with full Phase 1/1B results expected in H1 2027.
EQUITY | Aug 20, 2026, 11:01 AM UTC
L
AC Immune reports positive preliminary Phase 1 data for ACI-19764
AC Immune says preliminary Phase 1 data for its NLRP3 inhibitor ACI-19764 are positive, with no further details on the findings supplied in the alert.
EQUITY | Aug 20, 2026, 11:00 AM UTC